Aim To construct a novel double liposome (DLP) formulation for combined delivery and evaluate the pharmacokinetic property of the new.system by in vitro and in vivo methods.Methods Doxorubicin (DOX) and multi-drug resistance inhibitor bisdemethoxycurcumin (BCM) were encapsulated in different layer of double liposomes.DSC, XRD and TEM tests were performed to verify the DLP formation, the particle size, zeta potential were also examined and the release profiles were tested in PBS.In vitro cell uptake, MTT and apoptosis tests were performed, in vivo evaluation was based on pharmacokinetics and distribution study, the tumor inhibition was examined in mice.Results The formation of DLP was confirmed by chemical-physics study, DOX-BCM-DLP significantly facilitated the uptake of DOX compared to DOX-LP or free DOX in doxorubicin-resistance MCF-7/a cells, thus illustrated the highest in vitro cytotoxicity and apoptosis efficiency to tumor cells.DOX-BCM-DLP provided more DOX tumor sites accumulation in A549 tumor beating mice than DOX-LP while no significant changes of distribution in other tissues were observed, the results were re-examined by in-vivo imaging.Finally, anti-tumor tests suggest that this novel liposome preparation actually increased survival time of A549 tumor bearing mice with low toxicity.Conclusion delivering chemotherapy drug and P-gp inhibitor simultaneously using double liposomes may have potential for enhancing anti-tumor efficiency.